Tesaro, Inc. (TSRO) EPS Estimated At $-2.61

October 13, 2018 - By Ash

Tesaro, Inc. (NASDAQ:TSRO) LogoInvestors sentiment decreased to 0.93 in Q2 2018. Its down 0.21, from 1.14 in 2018Q1. It fall, as 59 investors sold Tesaro, Inc. shares while 44 reduced holdings. 29 funds opened positions while 67 raised stakes. 58.58 million shares or 3.28% less from 60.57 million shares in 2018Q1 were reported.
Macquarie Grp Incorporated Ltd reported 323,748 shares. Massachusetts-based Massachusetts Fincl Serv Ma has invested 0% in Tesaro, Inc. (NASDAQ:TSRO). Rhumbline Advisers stated it has 39,787 shares. 10,024 were accumulated by Kazazian Asset Management Limited Liability Com. 37,524 are owned by Impact Advsrs Limited Liability. America First Investment Limited Com invested 0.01% of its portfolio in Tesaro, Inc. (NASDAQ:TSRO). Fincl Bank Of New York Mellon holds 600,100 shares or 0.01% of its portfolio. Advsr Asset Mgmt has 3,957 shares. Geode Llc invested 0% in Tesaro, Inc. (NASDAQ:TSRO). Swiss Retail Bank reported 66,800 shares or 0% of all its holdings. Alliancebernstein L P reported 23,280 shares stake. Td Asset Mgmt invested in 0% or 62,569 shares. 7,779 were reported by Teacher Retirement Sys Of Texas. Price T Rowe Assocs Md has invested 0.02% in Tesaro, Inc. (NASDAQ:TSRO). Susquehanna Group Inc Ltd Liability Partnership has 0% invested in Tesaro, Inc. (NASDAQ:TSRO).

Since June 12, 2018, it had 0 insider buys, and 2 insider sales for $310,256 activity. Alleva Lawrence M also sold $307,920 worth of Tesaro, Inc. (NASDAQ:TSRO) on Tuesday, June 12.

Analysts expect Tesaro, Inc. (NASDAQ:TSRO) to report $-2.61 EPS on November, 6.They anticipate $2.14 EPS change or 455.32 % from last quarter’s $-0.47 EPS. After having $-3.04 EPS previously, Tesaro, Inc.’s analysts see -14.14 % EPS growth. The stock increased 5.05% or $1.95 during the last trading session, reaching $40.6. About 1.58 million shares traded. Tesaro, Inc. (NASDAQ:TSRO) has declined 70.32% since October 14, 2017 and is downtrending. It has underperformed by 85.94% the S&P500.

Tesaro, Inc. (NASDAQ:TSRO) Ratings Coverage

Among 10 analysts covering Tesaro (NASDAQ:TSRO), 8 have Buy rating, 0 Sell and 2 Hold. Therefore 80% are positive. Tesaro had 15 analyst reports since April 16, 2018 according to SRatingsIntel. The company was maintained on Wednesday, August 29 by Citigroup. The rating was upgraded by Barclays Capital on Wednesday, June 27 to “Buy”. The rating was maintained by Citigroup with “Buy” on Friday, May 4. The stock of Tesaro, Inc. (NASDAQ:TSRO) earned “Buy” rating by Bank of America on Friday, May 4. The company was maintained on Wednesday, May 2 by Argus Research. The rating was maintained by Citigroup on Thursday, May 31 with “Buy”. As per Monday, August 6, the company rating was downgraded by Bank of America. The company was maintained on Friday, May 4 by H.C. Wainwright. The firm has “Outperform” rating given on Friday, May 4 by Credit Suisse. Bank of America maintained Tesaro, Inc. (NASDAQ:TSRO) rating on Tuesday, September 11. Bank of America has “Neutral” rating and $38 target.

Tesaro, Inc., an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. The company has market cap of $2.23 billion. It markets Rolapitant, a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting under the VARUBI brand name. It currently has negative earnings. The firm is also developing Niraparib, an orally active and potent poly polymerase inhibitor, which is in various clinical trials to treat ovarian or breast cancers.

More notable recent Tesaro, Inc. (NASDAQ:TSRO) news were published by: Globenewswire.com which released: “TESARO Announces Data Presentations at the ESMO 2018 Congress” on October 09, 2018, also Seekingalpha.com with their article: “Key events next week – healthcare” published on October 12, 2018, Globenewswire.com published: “TESARO Announces Data Presentations at the SITC 2018 Annual Meeting” on October 01, 2018. More interesting news about Tesaro, Inc. (NASDAQ:TSRO) were released by: Seekingalpha.com and their article: “Premarket analyst action – healthcare” published on October 01, 2018 as well as Globenewswire.com‘s news article titled: “TESARO Announces Participation at Two Investor Conferences” with publication date: September 19, 2018.

Tesaro, Inc. (NASDAQ:TSRO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News